Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 5, 2025BiomedicinesOpen Access

Efficacy and Safety of the Combination of Durvalumab Plus Gemcitabine and Cisplatin in Patients with Advanced Biliary Tract Cancer: A Real-World Retrospective Cohort Study

View Full Paper
Ask AI
Bookmark
Share

Authors

EKE. KuriharaSKSatoru KakizakiMIMasashi Ijima

Discussion

Loading...

Member takes

Overview

Retrospective cohort study reports 25% overall response rate in advanced biliary tract cancer, suggesting effectiveness of GCD therapy.

Key Points

  • The overall response rate was 25% with gemcitabine and cisplatin treatment in 52 patients with biliary tract cancer.
  • Median progression-free survival of 8.6 months indicates potential effectiveness of GCD therapy in real-world practice.
  • Most patients experienced stable disease and the overall disease control rate was 78.8%, highlighting treatment's impact.
  • Immune-related adverse events were minimal, suggesting that GCD therapy is safe for patients with advanced biliary tract cancer.

Cite This Study

Kurihara et al. (2025) studied this question.

synapsesocial.com/papers/6895220c9f4f1c896c429701https://doi.org/10.3390/biomedicines13081915
View Full Paper
Ask AI
Bookmark
Share